|
|
Vaccine Detail
|
Tumor Cell Derivative Vaccine |
| Vaccine Information |
- Vaccine Name: Tumor Cell Derivative Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007075
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Preparation: Tumor cell vaccines were generated by irradiating 4T1 or EMT6 cells at 100 Gy using a Gammacell 1000 cesium irradiator (Ravindranathan et al., 2018).
- Description: This is for Leukemia Cancer (NCT00100971). A vaccine made of cancer cells, parts of cancer cells, or pure tumor antigens (substances isolated from tumor cells). A tumor antigen vaccine may stimulate the body's immune system to find and kill cancer cells (Ravindranathan et al., 2018; NCIT_C2341).
|
| Host Response |
|
|
| References |
NCIT_C2341: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2341]
NCT00100971: [https://clinicaltrials.gov/ct2/show/NCT00100971]
Ravindranathan et al., 2018: Ravindranathan S, Nguyen KG, Kurtz SL, Frazier HN, Smith SG, Koppolu BP, Rajaram N, Zaharoff DA. Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines. Breast cancer research : BCR. 2018; 20(1); 126. [PubMed: 30348199].
|
|
